Compare RLTY & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RLTY | IKT |
|---|---|---|
| Founded | 2022 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.5M | 274.9M |
| IPO Year | 2021 | 2020 |
| Metric | RLTY | IKT |
|---|---|---|
| Price | $13.80 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $5.55 |
| AVG Volume (30 Days) | 76.2K | ★ 559.3K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | ★ 9.35% | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $33.33 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.34 | $1.33 |
| 52 Week High | $16.41 | $2.61 |
| Indicator | RLTY | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 25.79 |
| Support Level | $13.34 | $1.59 |
| Resistance Level | $15.92 | $1.74 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 61.06 | 4.85 |
Cohen & Steers Real Estate Opportunities and Income Fund is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income. Its secondary investment objective is capital appreciation. The fund invests the majority of its managed assets in real estate-related investments and preferred and other income securities.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.